Pfizer's Coming for AbbVie's Market Share. ... (now that Humira is seeing competition from generics as a result of going over the patent cliff in the U.S. this year).

Pfizer’s revenue rose at an average annual rate of 25.6% from $41.7 billion in 2020 to $58.5 billion in 2023, while AbbVie’s revenue grew at an average rate of 6.5% from $45.8 billion to $54.3 ...

AbbVie (ABBV-1.53%) and Pfizer (PFE-1.88%) stand out as two of the best in the industry. So far this year, Pfizer has been the bigger winner in terms of stock performance .

In terms of its financial outlay, AbbVie is buying ImmunoGen for just over $10 billion in cash, so right off the bat it's clear that the scale of its commitment isn't as large as Pfizer's.

We compare AbbVie and Pfizer and determine which is a better high-yield pick for investors. Click here to know the results.

In a victory for AbbVie (ABBV), a U.S. federal judge ruled the drug maker did not unfairly thwart competition by striking deals with other companies that resolved patent lawsuits, but also ...

Another Humira copycat is primed to enter the U.S. market in 2023. Pfizer has settled with AbbVie for a nonexclusive intellectual property license to market its proposed Humira biosimilar in the ...

AbbVie and Pfizer currently offer two of the highest dividend payouts among major drugmakers, with respective yields of 3.8% and 3.7%, according to S&P Global Market Intelligence .

If you're looking for juicy dividend yields, you might want to check out big pharmaceutical stocks. AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE) stand out as two of the best in the industry.

In terms of its financial outlay, AbbVie is buying ImmunoGen for just over $10 billion in cash, so right off the bat it's clear that the scale of its commitment isn't as large as Pfizer's.

Specifically, AbbVie is presently staring down the pending patent expiration of its flagship anti-inflammatory medicine Humira. And Pfizer is fresh off of its break-up with Botox-maker Allergan ...